MARKET

LTRN

LTRN

Lantern Pharma Inc
NASDAQ
2.640
+0.080
+3.13%
Closed 16:10 02/06 EST
OPEN
2.590
PREV CLOSE
2.560
HIGH
2.672
LOW
2.575
VOLUME
45.49K
TURNOVER
0
52 WEEK HIGH
5.74
52 WEEK LOW
2.530
MARKET CAP
29.53M
P/E (TTM)
-1.5062
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LTRN last week (0126-0130)?
Weekly Report · 02/02 09:16
Weekly Report: what happened at LTRN last week (0119-0123)?
Weekly Report · 01/26 09:16
Lantern Pharma Showcases AI Platform for Rare Cancers
TipRanks · 01/23 13:08
Lantern Pharma Receives FDA Orphan Drug Designation For LP-284
NASDAQ · 01/20 15:14
Lantern Pharma gets orphan drug designation for LP-284 from FDA
TipRanks · 01/20 13:16
FDA Grants Orphan Drug Designation to Lantern Pharma's LP-284 for Soft Tissue Sarcomas
Reuters · 01/20 13:04
LANTERN PHARMA'S LP-284 RECEIVES FDA ORPHAN DRUG DESIGNATION FOR SOFT TISSUE SARCOMAS
Reuters · 01/20 13:00
Weekly Report: what happened at LTRN last week (0112-0116)?
Weekly Report · 01/19 09:17
More
About LTRN
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

Webull offers Lantern Pharma Inc stock information, including NASDAQ: LTRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LTRN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LTRN stock methods without spending real money on the virtual paper trading platform.